Seeking Alpha

Aegis hikes price target on Stemline citing SL-401 potential

  • Aegis boosts its price target on Stemline Therapeutics (STML -5.7%) to $70 (from $40). That's good for upside of around 141% from current levels.
  • Like Wedbush's David Nierengarten, analyst Ram Selvaraju likes SL-401 and thinks the drug will get marketing authorization for both blastic plasmacytoid dendritic cell neoplasm and AML, ultimately resulting in peak sales of $800M to $3B.
  • "STML is currently completing the final stages of a larger-scale manufacturing run for SL-401, which should provide sufficient cGMP-grade material to conduct additional clinical studies in BPDCN, AML and other niche hematological malignancies such as hairy cell leukemia," Selvaraju says.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs